Here Are the Specific Groups at Higher Risk for Severe COVID-19 Illness, Per the CDC

by Bill Vick | Apr 16, 2020 | Pulmonary Fibrosis

In this update, the Centers for Disease Control and Prevention (CDC) offers essential information for people at higher risk for severe illness due to COVID-19. *Please Note: This information is being shared directly from the CDC website . COVID-19 is a new disease and...

Galapagos teams up with Polish biotech Ryvu for early R&D collab

by Bill Vick | Apr 16, 2020 | Pulmonary Fibrosis

(Galapagos) Gilead Sciences-partnered Belgium biotech Galapagos has a lot of shots on goal, with many being tied up with its multibillion dollar deal with Gilead. But Galapagos is still working on its future pipeline, seemingly not wanting to be bought up by its...

Science and Technology Daily: Chinese Approach on Medical Treatment against COVID-19

by Bill Vick | Apr 16, 2020 | Pulmonary Fibrosis

BEIJING, April 16, 2020 /PRNewswire/ — A news report by Science and Technology Daily: Is there any specific drug to fight against COVID-19? When can we get access to the specific drug? These two questions are hard to answer for now. Developing the specific drug...

What are the underlying conditions causing more serious illness from coronavirus?

by Bill Vick | Apr 16, 2020 | Pulmonary Fibrosis

We’ve heard that elderly people and those with underlying health conditions are most at risk if they’re infected with coronavirus, but those can seem like really general terms. Who does that include? And why can they face more serious illness?...

‘Positive Feedback’ Received from US FDA for COVID-19 Human Trial

by Bill Vick | Apr 16, 2020 | Pulmonary Fibrosis

The fight goes on to rid the world of the COVID-19 coronavirus. And one Canadian company is on the forefront of the battle. And plans to help win it. Algernon Pharmaceuticals Inc. (AGN) ( CSE.AGN , OTCQB:AGNPF , Forum ), a clinical stage pharmaceutical development...